Bank of Montreal Can Increases Holdings in Repligen Co. (RGEN)

Bank of Montreal Can raised its position in shares of Repligen Co. (NASDAQ:RGEN) by 41.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 35,457 shares of the biotechnology company’s stock after purchasing an additional 10,425 shares during the period. Bank of Montreal Can owned 0.08% of Repligen worth $1,287,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. The Manufacturers Life Insurance Company grew its holdings in Repligen by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 26,402 shares of the biotechnology company’s stock valued at $1,095,000 after purchasing an additional 106 shares during the period. Parametric Portfolio Associates LLC boosted its holdings in shares of Repligen by 2.9% in the second quarter. Parametric Portfolio Associates LLC now owns 36,735 shares of the biotechnology company’s stock worth $1,522,000 after acquiring an additional 1,048 shares during the period. Voya Investment Management LLC boosted its holdings in shares of Repligen by 12.0% in the second quarter. Voya Investment Management LLC now owns 16,003 shares of the biotechnology company’s stock worth $663,000 after acquiring an additional 1,717 shares during the period. California Public Employees Retirement System boosted its holdings in shares of Repligen by 1.6% in the third quarter. California Public Employees Retirement System now owns 122,548 shares of the biotechnology company’s stock worth $4,696,000 after acquiring an additional 1,948 shares during the period. Finally, Nationwide Fund Advisors boosted its holdings in shares of Repligen by 2.4% in the third quarter. Nationwide Fund Advisors now owns 84,480 shares of the biotechnology company’s stock worth $3,237,000 after acquiring an additional 1,979 shares during the period. 83.48% of the stock is owned by institutional investors and hedge funds.

Shares of Repligen Co. (NASDAQ:RGEN) opened at $32.75 on Friday. Repligen Co. has a 12-month low of $29.56 and a 12-month high of $46.81. The stock has a market capitalization of $1,430.00, a price-to-earnings ratio of 55.51, a P/E/G ratio of 1.85 and a beta of 0.91.

In related news, VP Howard Benjamin sold 12,729 shares of the stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $35.34, for a total value of $449,842.86. Following the sale, the vice president now owns 36,554 shares in the company, valued at $1,291,818.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Anthony Hunt sold 8,970 shares of the stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $35.95, for a total value of $322,471.50. Following the completion of the sale, the chief executive officer now owns 83,613 shares in the company, valued at approximately $3,005,887.35. The disclosure for this sale can be found here. Company insiders own 1.50% of the company’s stock.

RGEN has been the subject of a number of analyst reports. JPMorgan Chase & Co. initiated coverage on Repligen in a report on Tuesday, December 5th. They issued an “overweight” rating and a $42.00 price target for the company. BidaskClub lowered Repligen from a “hold” rating to a “sell” rating in a report on Friday, January 19th. TheStreet lowered Repligen from a “b-” rating to a “c” rating in a report on Monday, November 13th. CL King initiated coverage on Repligen in a report on Monday, November 13th. They issued a “buy” rating and a $41.00 price target for the company. Finally, Citigroup initiated coverage on Repligen in a report on Friday, December 8th. They issued a “buy” rating and a $45.00 price target for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. Repligen has a consensus rating of “Buy” and a consensus price target of $44.38.

COPYRIGHT VIOLATION WARNING: “Bank of Montreal Can Increases Holdings in Repligen Co. (RGEN)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/17/bank-of-montreal-can-increases-holdings-in-repligen-co-rgen.html.

About Repligen

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply